Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study

This retrospective study analyzed the EBMT registry data regarding adult patients with MBC who underwent HDC and ASCT between 2000 and 2015. In the absence of robust prospective trials, the EBMT registry remains an important source to survey indications, outcomes, and clinical risk factors. OS and PFS were defined as time to death from any cause from the date of the first ASCT, and as the time from first transplantation to progression or death, respectively. OS and PFS were calculated through Kaplan–Meier (KM) analysis. A comparative analysis was conducted to select covariates associated with PFS by log-rank test. In Cox models, data were expressed as hazard ratio (HR), 95% CI, and p values.